Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404841 | 1.00 | OPRM1 (0.34) | OPRM1CYP2A6MMP2MMP9OPRL1 | |
| SCHEMBL6400860 | 0.89 | CYP2A6 (0.34) | CYP2A6MMP2MMP9TPSAB1MRGPRX4 | |
| SCHEMBL6400863 | 0.89 | CYP2A6 (0.34) | CYP2A6MMP2MMP9TPSAB1MRGPRX4 | |
| SCHEMBL6400972 | 0.89 | CA12 (0.35) | OPRM1CYP2A6MMP2MMP9TPSAB1 | |
| SCHEMBL6401597 | 0.89 | CA12 (0.35) | OPRM1CYP2A6MMP2MMP9TPSAB1 | |
| SCHEMBL6399715 | 0.89 | MMP2 (0.39) | CYP2A6MMP2MMP9TPSAB1MRGPRX4 | |
| SCHEMBL6400319 | 0.89 | MMP2 (0.39) | CYP2A6MMP2MMP9TPSAB1MRGPRX4 | |
| SCHEMBL6429205 | 0.86 | CA12 (0.34) | CYP2A6MMP2MMP9MRGPRX4CA12 | |
| SCHEMBL6429202 | 0.86 | CA12 (0.34) | CYP2A6MMP2MMP9MRGPRX4CA12 | |
| SCHEMBL6400486 | 0.85 | CYP2A6 (0.33) | CYP2A6KCNH2MCHR2MCHR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | claimed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | claimed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | OPRM1 1274/4885CYP2A6 486/4885MMP2 2931/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | OPRM1 1172/4885CYP2A6 459/4885MMP2 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.